NasdaqGS - Nasdaq Real Time Price USD

Autolus Therapeutics plc (AUTL)

Compare

1.4300

+0.0800

+(5.93%)

At close: 4:00:01 PM EDT

1.5500

+0.12

+(8.39%)

After hours: 6:20:51 PM EDT

April 2025's Top Penny Stocks To Watch

The market is up 8.4% in the last 7 days, with all sectors gaining ground, and over the past 12 months, it has risen by 5.9%, with earnings forecasted to grow by 13% annually. Penny stocks may be a throwback term, but the opportunities they represent are far from old news; these typically smaller or newer companies present an underappreciated chance for growth at lower price points. When combined with strong balance sheets and solid fundamentals, penny stocks can offer upside without many of...

Simply Wall St. yesterday

ARDX

AUTL
+5.93%
PL
Autolus Therapeutics price target lowered to $10 from $11 at Truist

Truist lowered the firm’s price target on Autolus Therapeutics (AUTL) to $10 from $11 and keeps a Buy rating on the shares. The firm is updating its model and estimates for Autolus, slightly lowering our price target as it removes AUTO4 from its valuation, the analyst tells investors in a research note. Truist adds it is assigning no value to autoimmune indications, but this could change following Autolus’ April R&D day. Published first on TheFly – the ultimate source for real-time, market-movin

TipRanks 15 days ago

AUTL
+5.93%
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24th Annual Needham Virtual Healthcare Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT / 14:30pm BST. A webcast of the fireside chat will

GlobeNewswire 15 days ago

AUTL
+5.93%
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

LONDON, April 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will host an R&D investor event on Wednesday, April 23, 2025 at 8:30am EDT / 13:30pm BST. Autolus will present an update on clinical pipeline programs, including plans to expand the obe-cel opportunity. The Company expects to report initial data in si

GlobeNewswire 16 days ago

AUTL
+5.93%
Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings Call Highlights: Financial Growth Amid Rising Costs

Autolus Therapeutics PLC (AUTL) reports significant cash reserves and strategic advancements despite increased operational expenses.

GuruFocus.com 27 days ago

AUTL
+5.93%
BNTX
Q4 2024 Autolus Therapeutics PLC Earnings Call

Q4 2024 Autolus Therapeutics PLC Earnings Call

Thomson Reuters StreetEvents 27 days ago

AUTL
+5.93%
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

AUCATZYL® (obecabtagene autoleucel) U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and EMA marketing authorizations expected in H2 2025Initial six patients dosed in Phase 1 dose confirmation trial in Systemic Lupus Erythematosus (SLE) Company to provide clinical development program updates, including plans for expansion in autoimmune diseases, at R&D investor event to be held on Apri

GlobeNewswire 28 days ago

AUTL
+5.93%
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2024 financial results and operational highlights before open of US markets on Thursday, March 20, 2025. Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company’s

GlobeNewswire last month

AUTL
+5.93%
Is Autolus Therapeutics plc (AUTL) the Best UK Growth Stock to Buy Now?

We recently compiled a list of the 10 Best UK Growth Stocks to Buy Now. In this article, we are going to take a look at where Autolus Therapeutics plc (NASDAQ:AUTL) stands against the other UK growth stocks. The start of this year has marked interesting developments for the UK market. The main stock market index […]

Insider Monkey last month

AUTL
+5.93%
Autolus Therapeutics to Participate in Upcoming Investor Conferences

LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences. Jefferies Biotech on the Beach SummitManagement to host investor meetingsDate: March 11, 2025Location: Miami, FL Leerink Global Biopharma ConferenceFireside Chat PresentationDate and time: March 12, 2025

GlobeNewswire last month

AUTL
+5.93%
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, being held from February 12-15, 2025, in Hawai'i Convention Center, Honolulu, HI. “Building on our data presented at ASH

GlobeNewswire 2 months ago

AUTL
+5.93%
Autolus Therapeutics Provides Business Updates and 2025 Overview

- Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th - National Comprehensive Cancer Network® adds AUCATZYL® to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - Company to provide clinical development program updates, including plans for expansion into autoimmune disease, at April 23rd R&D investor event LONDON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutic

GlobeNewswire 3 months ago

AUTL
+5.93%
Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now?

We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Autolus Therapeutics plc (NASDAQ:AUTL) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from […]

Insider Monkey 3 months ago

AUTL
+5.93%
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation and three poster presentations at the American Society of Hematology (ASH) Annual Meeting, being held from December 7-10, 2024, in San Diego. “Our oral presentation at ASH this year with data from the FELIX trial demonstrates that obe-cel treatment produces a high incidence of

GlobeNewswire 4 months ago

AUTL
+5.93%
Autolus Therapeutics plc (AUTL): A Bull Case Theory

We came across a bullish thesis on Autolus Therapeutics plc (AUTL) on wallstreetbets Subreddit Page by _Ukey_. In this article, we will summarize the bulls’ thesis on AUTL. Autolus Therapeutics plc (AUTL)’s share was trading at $3.20 as of Dec 3rd. Autolus Therapeutics is a biopharmaceutical company focused on developing innovative CAR-T cell therapies for the treatment […]

Insider Monkey 4 months ago

AUTL
+5.93%
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with obe-cel with a median follow-up of 20.3 monthsLow incidence of immune-related toxicity: Grade ≥ 3 CRS and ICANS were observed in 2.4% and 7.1% of infused patients respectivelyHigh rates of durable response: 12-month event free survival of 49.5% in all patients who received at least one infusion LONDON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early-com

GlobeNewswire 4 months ago

AUTL
+5.93%
Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs upgraded Autolus Therapeutics (AUTL) to Buy from Neutral with a price target of $7.60, up from $7. The recent approval of lead asset Aucatzyl represents a de-risking event for the company’s technology platform and manufacturing facilities and the label granted by the FDA supports Aucatzyl’s differentiated safety profile, contends the firm, which sees “a significant dislocation between the company’s fundamental valuation and current market value.” Published first on TheFly – the ult

TipRanks 4 months ago

AUTL
+5.93%
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023)

Autolus Therapeutics ( NASDAQ:AUTL ) Third Quarter 2024 Results Key Financial Results Net loss: US$82.1m (loss widened...

Simply Wall St. 4 months ago

AUTL
+5.93%
Syncona Ltd (LSE:SYNC) Half Year 2025 Earnings Call Highlights: Navigating Market Challenges ...

Despite a decline in NAV and portfolio value, Syncona Ltd (LSE:SYNC) remains optimistic with strategic investments and leadership enhancements.

GuruFocus.com 4 months ago

^YH103

AUTL
+5.93%
Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Autolus Therapeutics PLC (AUTL) reports significant progress with FDA approval of AUCATZYL, robust financial positioning, and strategic challenges in its Q3 2024 earnings call.

GuruFocus.com 5 months ago

AUTL
+5.93%

Performance Overview

Return	AUTL	MSCI WORLD (^990100-USD-STRD)
YTD	-35.29%	-6.30%
1-Year	-70.58%	+5.88%
3-Year	-64.60%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Autolus Therapeutics plc (AUTL)

April 2025's Top Penny Stocks To Watch

Autolus Therapeutics price target lowered to $10 from $11 at Truist

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings Call Highlights: Financial Growth Amid Rising Costs

Q4 2024 Autolus Therapeutics PLC Earnings Call

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Is Autolus Therapeutics plc (AUTL) the Best UK Growth Stock to Buy Now?

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Autolus Therapeutics Provides Business Updates and 2025 Overview

Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now?

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics plc (AUTL): A Bull Case Theory

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs

Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023)

Syncona Ltd (LSE:SYNC) Half Year 2025 Earnings Call Highlights: Navigating Market Challenges ...

Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Performance Overview